Allianz Preferred Medical

Allianz Preferred Medical is an annual indemnity individual hospitalisation product offering three plan tiers (Standard, Extra, Premier) with annual coverage limits stepping from Rp 1 billion to Rp 20 billion and geographic scope stepping from Indonesia-only to Asia-plus-Australia. The product is a “modern medical card” structure with a 5% no-claim premium-renewal rebate, a Rp 15 million baseline death benefit (rising to Rp 30 million from age 80) layered onto the medical cover, and a Risiko Sendiri (deductible/co-payment) framework that is already aligned with the new POJK 36/2025 co-payment regime taking effect January 2026.

Category: health (Conventional + Syariah indemnity hospital plans treated as one market per project convention) Products in category analyzed: 35 catalogued (~14 with extracted PDFs as of 2026-04-26) This product’s position: Premium-tier indemnity plan with very high annual limits (Rp 20 billion in Premier) and a small embedded life cover; targets the upper-middle and affluent agency segment.

A “typical” Indonesian individual indemnity health product in this inventory offers 1–3 plan tiers, an annual room-and-board cap, an inner-limit benefit table, an annual policy term that auto-renews to a stated maximum age, an Indonesia or Indonesia+ASEAN coverage area, and a deductible/co-payment of some form. Newer designs since the 2025 POJK announcements increasingly include Risiko Sendiri tiers, hospital-network preferences, and major-illness extensions. Allianz Preferred Medical sits in the upper end of this distribution on annual limit, geographic scope, and rider integration.

Quantifiable benchmarking across the health category is currently limited because most peer products’ detailed extraction is HTML-only (Path A) and benefit-table specifics are PDF-locked. The table below is qualitative-comparative based on observed product structures in the inventory.

[Limited quantitative benchmarking available — category data coverage is roughly 40% on PDF and most line-item benefit numbers fall below the 60% coverage threshold. Analysis relies more heavily on qualitative observations below.]

Quantifiable position summary: On entry/renewal age, annual limits, and geographic scope, Allianz Preferred Medical positions at the top of the catalogued category. On premium affordability and tier granularity, it is mid-pack. The brochure-disclosed sample of Rp 18.83 million annual premium for a 30-year-old at Plan Premier puts the top tier squarely in the affluent agency-customer segment rather than the mass market.

• Coverage ceilings well above category norms — Annual limits of Rp 15 billion (Extra) and Rp 20 billion (Premier) plus a separate Rp 15–20 billion supplementary annual cap give clients a shock-absorber that sits 1.5–10x higher than the typical individual plan in the inventory. This matters in 2026 because medical inflation has run at 20–26% in Indonesia in recent years and any annual cap below Rp 5 billion increasingly fails to cover a serious overseas treatment.
• Embedded major-illness benefit reduces rider stack — The plan’s “Manfaat Penyakit Major” pays cancer outpatient up to Rp 120 million per year, dialysis up to Rp 60 million per year, and palliative care up to Rp 250 million in Extra/Premier — features that competitors typically push to a separate critical-illness or hospital-cash rider. This simplifies the agent-pitch and reduces total cost of ownership versus a base plan plus separate riders.
• Geographic reach extending to Asia + Australia — Premier’s coverage area including Australia is rare among the catalogued domestic peers, which mostly stop at Indonesia or ASEAN. This is meaningful for Indonesian HNW customers who travel for cancer or cardiac treatment to Singapore, Australia, or Japan — and the product’s Asia-only Extra tier already excludes the three most expensive geographies (Singapore, Hong Kong, Japan), giving customers a sensible step-down option.
• Renewable to age 100 with entry to age 75 — Among catalogued products, the upper entry/renewal envelope is broad. This is genuinely competitive against incumbents that cap renewal at 70 or 85 and matters for the legacy-planning conversation Allianz’s agency channel runs.

• Plan Standard is heavily exclusion-loaded versus Extra/Premier — The Standard tier explicitly excludes HIV/AIDS, home care, traditional medicine, and the entire “Penyakit Khusus” category (hernia, tumours, kidney stones, varicose veins and roughly 15 other common conditions) for the first policy year, and home care for the entire term. This creates a “bait-and-disclose” risk in the field if agents underplay how different Standard’s protection is from the headline Extra/Premier benefits typically used in marketing.
• Annual policy with inflation-exposed renewal pricing — As an annual indemnity product, the contract gives the insurer the right to re-rate at every renewal. With Indonesian medical inflation projected near 15% in 2026 and the new POJK 36/2025 co-payment regime expected to compress insurer claims ratios only partially, customers face material renewal-premium uncertainty. The 5% no-claim rebate softens but does not offset double-digit re-rating.
• Sample annual premium of Rp 18.83 million at age 30 for Premier — At roughly USD 1,180/year for a healthy 30-year-old, the headline price for the top plan is well above the mass-market segment that drives Allianz’s volume in agency. The product is structurally an upper-segment offer, which limits the agent’s prospect funnel relative to multi-tier plans that have a Rp 4–8 million entry point.
• Risiko Sendiri (co-payment) interacts with hospital-network tiering — The deductible amount the customer pays per inpatient is determined by hospital category (Preferred Network vs Other Network) and the option chosen. While this is a reasonable design, in agency-led sales it adds explanation complexity that mid-tier competitors with simpler co-pay structures may exploit at the kitchen-table.

- POJK 36/2025 co-payment regime favours already-structured products — From January 2026 every Indonesian health insurance policy must include a 10% co-payment with caps of Rp 300,000 outpatient / Rp 3,000,000 inpatient and a Medical Advisory Board (DPM). Allianz Preferred Medical’s existing Risiko Sendiri framework is structurally aligned, meaning re-papering effort is small and Allianz can market continuity while peers are re-issuing policies. Allianz’s brand and DPM-readiness should let it win mind-share during the transition window.

- Indonesian medical inflation reinforces high-limit positioning — With medical inflation tracking near three times general CPI and continuing to outrun wage growth, the value proposition of a Rp 15–20 billion annual cap strengthens each year. This is exactly the macro tailwind that supports premium-tier indemnity plans over basic hospital cash plans, especially among the 30–50 age cohort that has earnings to protect.

- Affluent middle-class growth in Java metros and Surabaya–Medan–Makassar belt — World Bank and OJK roadmap data point to faster premium growth outside Jakarta in 2026, with insurance penetration still well below ASEAN peers. Allianz Star Network’s agency footprint in these cities pairs naturally with a product that solves the “I might need overseas treatment one day” anxiety driving purchases in this cohort.

- Bundling with Allianz Smartlink / Smartwealth — Because the product carries an embedded Rp 15 m death benefit, it can be sold next to one of Allianz’s investment-linked or savings products as the family medical-shield component without overlapping the life-cover space. This bundle plays well against bancassurance-led competitors that push standalone unit-linked.

—

- Co-payment compliance levels the field for laggards — POJK 36/2025 forces every competitor to add co-payment by January 2026 — meaning Allianz’s existing Risiko Sendiri-based design becomes structurally less differentiated by mid-2026. Competitors that re-launch with cleaner, simpler co-payment UX may neutralise this advantage in the agent narrative within 6–12 months.

- Bancassurance distribution pressure on premium-tier health — Bank distribution partners (Mandiri, BCA, BNI) increasingly push their own captive insurer products through their channels, with annual limits in the Rp 5–10 billion range and lower retail prices. As high-net-worth deposit holders are the primary target for premium-tier plans, this distribution overlap may compress agency conversion in the upper-affluent segment.

- DPM (Medical Advisory Board) and utilisation-review costs — POJK 36/2025 also mandates a Medical Advisory Board and stronger utilisation review across every insurer. Compliance cost is borne by the insurer, but is highly likely to be priced into renewal premiums. If renewal increases at Allianz cluster above 12–15% in 2026, churn risk to lower-tier products and self-insurance rises among the price-sensitive top-half of the customer base.

- Strong competition from Prudential PRUSolusi Sehat Plus and AIA HSBC plans on annual limit narrative — These competitor flagships also offer high-limit and broad geographic plans. To the extent that customer research increasingly happens digitally before agent meetings (per OJK’s digital-channel push), Allianz’s agency-only distribution loses some upper-funnel share to bancassurance/digital channels that surface comparison information sooner.

—

• The product is structurally a 2026-ready plan: tiered Risiko Sendiri, embedded major-illness, broad geographic reach, and high annual limits all address themes that POJK 36/2025 and rising medical inflation are forcing across the industry. Its competitive moat is more about head-start on POJK readiness than about feature uniqueness.
• The Standard tier’s pre-existing Penyakit Khusus exclusion (which lapses after the first renewal) is an underappreciated agent-talk-track risk. Field training that walks customers explicitly through the Year-1 / Year-2 difference would reduce mis-selling claims and harden the renewal-retention story.
• For Legacy Income’s positioning: this product’s main value to agents is a “premium-tier benchmark to triangulate against.” Allianz/Tokio Marine agents can use Preferred Medical’s Rp 20 billion cap and Asia+Australia coverage as the high-water mark in agent-prospect conversations, which positions the agent as a market expert even when the eventual sold product is something simpler and lower-priced.

High-confidence elements (drawn directly from RIPLAY/brochure documents):

• Three plan tiers (Standard, Extra, Premier) with annual limits of Rp 1 bn / Rp 15 bn / Rp 20 bn and matching supplementary caps
• Geographic coverage Indonesia / Asia ex Singapore-HK-Japan / Asia + Australia
• Death benefit Rp 15 m baseline rising to Rp 30 m from age 80
• Entry age 1 month – 75 years; renewal to age 100
• 5% no-claim renewal rebate available on auto-debit
• Risiko Sendiri (deductible) tiered to hospital network category
• Major-illness benefits embedded (cancer outpatient Rp 120 m, dialysis Rp 60 m, palliative Rp 250 m at Extra/Premier)
• Standard tier’s first-year Penyakit Khusus and HIV/AIDS exclusions
• Sample annual premium Rp 18.83 m for age-30 male Plan Premier

Inferred elements (reasoned but not document-backed):

• Positioning as “premium-tier” rather than mass-market — based on sample premium and benefit ceilings
• Agency-channel-only distribution — based on RIPLAY listing Allianz Star Network as marketing channel, but bancassurance variants may exist
• Comparative position against the rest of the 35-product category — the per-product database is incomplete

Data gaps (relevant information not available in source documents):

• Specific Risiko Sendiri amounts per Plan and Network category (RIPLAY shows scenarios but not the deductible matrix in extractable form)
• Premium tables by age, gender, and plan (only one sample illustrated)
• Underwriting requirements thresholds (medical exam, financial questionnaire triggers)
• Annual claim ratio, persistency, and renewal-rate experience

Extraction quality: medium — RIPLAY extracted to ~914 lines of clean text; brochure to ~807 lines; benefit table fine-print readable but some multi-column tables fragmented.

This analysis is generated by AI and may contain mistakes. Please exercise discretion.